<DOC>
	<DOCNO>NCT02829957</DOCNO>
	<brief_summary>A large proportion woman menstruate potential newly diagnose VTE atrial fibrillation , treat apixaban less menstrual blood loss patient randomized rivaroxaban .</brief_summary>
	<brief_title>RAMBLE - Rivaroxaban vs. Apixaban Heavy Menstrual Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Nonpregnant woman , age 1850 , Objectively diagnose VTE atrial fibrillation within previous 30 day , menstrual cycle since diagnosis Patient report active menstruation , require &gt; 3 menstrual period previous 6 month Clinical plan patient agreement treat oral anticoagulation 3 month long Patients must work mobile phone Package insert exclusion Eliquis ( Apixaban ) Xarelto ( Rivaroxaban ) : [ active pathological bleeding severe hypersensitivity reaction XARELTO ELIQUIS ( e.g. , anaphylactic reaction ) ] Plan become pregnant next three month . Concomitant prescribe use aspirin thienopyridine platelet inhibit drug Plan surgical hysterectomy endometrial ablation Known uterine cancer Von Willebrand 's disease , hemophilia Known coagulopathy liver disease Conditions likely preclude adherence study procedure : Active intravenous drug use , know alcoholism , homelessness , uncontrolled psychiatric illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>